Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  paclitaxel albumin-stabilized nanoparticle formulation
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 152 for your search:
Start Over
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Phase: Phase IV
Type: Treatment
Status: Active
Age: 70 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-NSCL-005, NCT02151149
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000513169, WHC-MRI-GU-2006-097, NCT00397761
Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: aesa, NCT01647672
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-MBC-001, 2013-000113-20, NCT01881230
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1137-CA, NCT02436668
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO28047, 2011-005334-20, NCT01572038
Study of Nab-Paclitaxel in High Risk Early Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: GBG 68, NCT01690702
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-PANC-003, 2013-003398-91, NCT01964430
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-NSCL-003, NCT02027428
A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GO29537, 2014-003206-32, NCT02367781
A Study of MPDL3280A in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: WO29522, 2014-005490-37, NCT02425891
Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AAAC1114, NCT00583349
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 and over
Sponsor: Other
Protocol IDs: HCI53993, NCT00748553
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1130, NA_00047491, NCT01431794
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PCRT 11-002, NCT01488552
Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCC-GI-01, NCT01693276
A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: PACT-19, 2012-001763-75, NCT01730222
Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCRT 12-001, NCT01893801
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 13C.387, 2013-035, NCT01938833
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-PST-001, NCT01962103
First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: VA2012/25, NCT01964287
Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: OCTO_063, NCT02024009
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1312169092, NCT02065466
Start Over